Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Tegafur

Oxaliplatin

Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.

Patients will not receive NAC before the gastrectomy and ERAS.

NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.

NAC group

Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.

Surgery alone group

Zhi-Wei JIANG, Ph.D.

Jian ZHAO, Ph.D.

Patients with advanced gastric cancer received neoadjuvant chemotherapy undergo enhanced recovery after surgery (ERAS) programs.

In recent years, enhanced recovery after surgery (ERAS) programs were applied in gastrectomy in areas with a high prevalence of gastric cancer, such as China and Japan, confirming that ERAS programs accelerate the postoperative rehabilitation of gastric cancer patients without increasing the occurrence rate of postoperative complications. However, in most studies on ERAS for gastric cancer, patients who received neoadjuvant chemotherapy were excluded. Investigators designed this study aimed to evaluate whether patients who receive neoadjuvant chemotherapy can enrolled into enhanced recovery after surgery programs for locally advanced gastric cancer.

This study is a single-center, parallel, open-label randomized controlled trial.

Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy

The Application of Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in Enhanced Recovery After Surgery Programs for Radical Gastrectomy

The results and IPD will be considered to share in published articles.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy	NCT03238404	Gastric Cancer	NAC group Surgery alone g...	18 Years - 75 Years	Jinling Hospital, China
Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy	NCT03238404	Gastric Cancer	NAC group Surgery alone g...	18 Years - 75 Years	Jinling Hospital, China
Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy	NCT03238404	Gastric Cancer	NAC group Surgery alone g...	18 Years - 75 Years	Jinling Hospital, China

Spots Global Cancer Trial Database for surgery alone group